PolyPid (PYPD) director details shares and vested stock options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
PolyPid Ltd. director Krinsky Itzhak filed an initial ownership report showing a mix of ordinary shares and stock options. He directly holds 833 Ordinary Shares. He also holds several stock option awards over Ordinary Shares, including 6,500 shares at an exercise price of $4.2400 expiring on July 2, 2034 and 14,440 shares at $2.6700 expiring on June 25, 2035. Additional options cover smaller amounts of shares at exercise prices of $11.4000 and $23.0700 with expiration dates between 2029 and 2033. Footnotes state that most of these options are already fully vested, while the June 25, 2025 grant vests quarterly until May 12, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Krinsky Itzhak
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 312 shares (Direct);
Ordinary Shares — 833 shares (Direct)
Footnotes (1)
- The options were granted on May 5, 2023 and fully vested as of May 5, 2024. The options were granted on August 7, 2019 and fully vested as of January 2, 2022. The options were granted on April 13, 2021 and fully vested as of April 13, 2022. The options were granted on May 3, 2022 and fully vested as of May 3, 2023. The options were granted on July 2, 2024 and fully vested as of July 2, 2025. The options were granted on June 25, 2025 and vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.
FAQ
What does PolyPid (PYPD) director Krinsky Itzhak report in this Form 3?
Krinsky Itzhak reports his initial ownership in PolyPid, including 833 Ordinary Shares and multiple stock option awards. The options cover different numbers of Ordinary Shares at various exercise prices and expiration dates, with most already fully vested according to the footnotes.
What are the largest stock option positions reported by Krinsky Itzhak in PYPD?
The largest option positions are for 14,440 Ordinary Shares at an exercise price of $2.6700 expiring on June 25, 2035, and 6,500 Ordinary Shares at $4.2400 expiring on July 2, 2034. Both are held directly and relate to previously granted awards.
Are Krinsky Itzhak’s PolyPid (PYPD) stock options vested?
Footnotes state that options granted on May 5, 2023; August 7, 2019; April 13, 2021; May 3, 2022; and July 2, 2024 are fully vested. Options granted on June 25, 2025 vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.
Does this PolyPid (PYPD) Form 3 show any insider buying or selling?
No specific purchases or sales are shown. The entries are labeled as holdings, with transaction direction marked as unknown and no buy or sell codes. The filing mainly lists existing Ordinary Share and stock option positions for director Krinsky Itzhak.
What are the exercise prices and expirations of Krinsky Itzhak’s other PYPD options?
Additional options cover 312 Ordinary Shares at $11.4000 expiring on May 5, 2033, plus 597, 299 and 312 shares at $23.0700 expiring on August 7, 2029, April 13, 2031, and May 3, 2032, respectively.